{"preliminary_commentary":{"by_channel":{"x_thread":11,"youtube":3,"podcast":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03946670\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"STIMULUS-MDS1","nct_id":"NCT03946670","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=stimulus-mds1-nct03946670. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"STIMULUS-MDS1","arms":[{"description":"Patients are taking MBG453 plus hypomethylating agents","label":"MBG453 + hypomethylating agents","type":"EXPERIMENTAL"},{"description":"Patients are taking placebo plus hypomethylating agents","label":"Placebo + hypomethylating agents","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2024-07-15","type":"ACTUAL"},"conditions":["Myelodysplastic Syndromes"],"enrollment":{"count":127,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"MBG453","otherNames":["Sabatolimab"],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"},{"name":"Hypomethylating agents","otherNames":[],"type":"DRUG"}],"last_update":"2026-01-13","lead_sponsor":"Novartis Pharmaceuticals","official_title":"A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria","overall_status":"TERMINATED","phases":["PHASE2"],"primary_completion_date":{"date":"2022-04-26","type":"ACTUAL"},"primary_outcomes":[{"measure":"Complete Remission (CR) Rate","timeFrame":"average of 7 months"},{"measure":"Progression Free Survival (PFS)","timeFrame":"approx. 32 months"}],"references":[{"citation":"Zeidan AM, Ando K, Rauzy O, Turgut M, Wang MC, Cairoli R, Hou HA, Kwong YL, Arnan M, Meers S, Pullarkat V, Santini V, Malek K, Kiertsman F, Niolat J, Ramos PM, Menssen HD, Fenaux P, Miyazaki Y, Platzbecker U. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 2024 Jan;11(1):e38-e50. doi: 10.1016/S2352-3026(23)00333-2. Epub 2023 Dec 5.","pmid":"38065203","type":"DERIVED"}],"start_date":{"date":"2019-06-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).","url":"https://clinicaltrials.gov/study/NCT03946670"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/stimulus-mds1-nct03946670"}